Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05df0446a200da441dfc383c3f3a5c37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_809bebf8e2f3dc1cf1f4ab4d9780da1f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fad57abc23a66d5aafc44913546f294e |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
filingDate |
2011-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2016-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58e227d4d332d3115a00ca75238d1da3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce29d2246f1d7ad8aff6f7b2238ccbb2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fca5b17e05bb54e77c5022d0d2314063 |
publicationDate |
2016-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9403882-B2 |
titleOfInvention |
Sulfation of Wnt pathway proteins |
abstract |
Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Additionally provided is a method of enhancing a Wnt signaling pathway comprising contacting an LRP5/6 receptor in the Wnt signaling pathway with either of the above-described compositions that comprise a sequence of a sclerostin fragment or is capable of inhibiting sclerostin binding to an LRP, where the tyrosine or tyrosine analog is not sulfated, in a manner sufficient to enhance the Wnt signaling pathway. Further provided is a method of treating a subject having a disease exacerbated by inhibition of a Wnt signaling pathway comprising administering either of the above-described compositions that comprise a sequence of a sclerostin fragment or is capable of inhibiting sclerostin binding to an LRP, where the tyrosine or tyrosine analog is not sulfated, to the subject in a manner sufficient to reduce the inhibition of the Wnt signaling pathway. Also, a method of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner is provided. The method comprises adding the above-described composition that is capable of inhibiting binding of a protein ligand to its binding partner to the protein ligand and its binding partner in a manner sufficient to inhibit binding of the protein ligand to its binding partner. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10328120-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017066820-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11167011-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017198033-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10626170-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11639382-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11667703-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10899827-B2 |
priorityDate |
2010-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |